U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07475559) titled 'JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors' on March 09.
Brief Summary: This is a Phase I, open-label, multicenter, first-in-human study to evaluate the safety, tolerability, PK/pharmacodynamic (PD) characteristics, and anti-tumor activity of JSKN016HC in subjects with advanced malignant solid tumors.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor Malignancies
Intervention:
DRUG: JSKN016HC
JSKN016HC is a subcutaneously injectable formulation of a bispecific ADC targeting HER3 and TROP2 (the main active ingredient is JSKN016).
Recruitment Status: NOT_YET_RE...